Charge-Modified Mannosylated Dextran Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current mannosylated carbohydrate polymers, such as tilmanocept, face challenges in off-target localization to areas like the liver and spleen, limiting their effectiveness in targeting tumors and other inflammatory sites due to non-specific binding to CD206 expressing cells, necessitating the development of alternative strategies to enhance target specificity and reduce off-target localization.

Innovation Solution

Administering a blocking compound with a different net charge, either polyanionic or neutral, in conjunction with a polycationic mannosylated carbohydrate polymer therapeutic or diagnostic compound to selectively target CD206 expressing cells in tumors and other inflammatory sites, thereby reducing off-target localization and increasing target specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mannosylated carbohydrate polymers are used to target CD206 expressing cells in tumors and inflammatory sites, then target tissue uptake is improved, but off-target localization to liver and spleen increases

Engineering Contradiction:

Improvetarget tissue uptakeVSAvoidoff-target localization

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the net charge of mannosylated carbohydrate polymers from neutral to polycationic. This charge modification alters the biodistribution pattern, reducing off-target accumulation in liver and spleen while maintaining or enhancing target tissue uptake. The charge parameter change enables selective interaction with target tissues through electrostatic mechanisms.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses oppositely charged polyanionic blocking compounds as intermediaries to compete for binding sites on CD206 expressing cells in off-target organs. These blocking compounds act as mediators that preferentially bind to liver and spleen macrophages, preventing the therapeutic polycationic mannosylated carbohydrate polymer from localizing to off-target sites while allowing target tissue penetration.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If the net charge on mannosylated carbohydrate polymers is altered to reduce off-target binding, then off-target localization is reduced, but binding affinity to CD206 expressing cells may be compromised

Engineering Contradiction:

Improveoff-target bindingVSAvoidbinding affinity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies local quality by creating spatially differentiated binding behavior through charge modification. The polycationic mannosylated carbohydrate polymer exhibits selective binding characteristics: strong affinity for target tissue CD206 receptors due to electrostatic attraction and tissue penetration, while showing reduced off-target binding through competitive inhibition by polyanionic blocking compounds at liver and spleen sites.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs a composite therapeutic system combining polycationic mannosylated carbohydrate polymer with polyanionic blocking compounds. This composite approach allows the two components to work synergistically: the polycationic therapeutic agent provides enhanced target penetration and binding, while the polyanionic blocking compound selectively occupies off-target binding sites, achieving both high target affinity and reduced off-target localization simultaneously.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the delivery of therapeutic or diagnostic agents to target tissues by minimizing binding to off-target sites like the liver and spleen, allowing for increased localization to tumors and inflammatory areas while maintaining or improving binding to CD206 expressing cells in target tissues.

Implementation Method 1

Administering a blocking compound with a different net charge, either polyanionic or neutral, in conjunction with a polycationic mannosylated carbohydrate polymer therapeutic or diagnostic compound

Methodology Applied

Scientific EffectElectrostatic interaction: Electrostatics

Implementation Method 2

Methodology Applied

Scientific EffectCompetitive binding: Adsorption

Data Source

PatentUS12178829B2Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking

Publication Date: 2024.12.31 NAVIDEA BIOPHARMACEUTICALS INC

AI summary

Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate polymeric therapeutic or diagnostic compound to off-target sites. Mannosylated carbohydrate polymers are synthesized to be modified to be either polyanionic (i.e., net negatively charged) or electrostatically neutral, and using these polyanionic or neutral mannosylated carbohydrate polymers as competitors for polycationic (i.e., net positively charged) mannosylated carbohydrate polymers carrying small molecule drug payloads or imaging moieties to CD206 expressing cells in target tissues, such as tumors or other sites of inflammation.